Mutation-specific Fabry disease patient-derived cell model to evaluate the amenability to chaperone therapy

Patients with Fabry disease (FD) and amenable mutations can be treated with the chaperone migalastat to restore endogenous α-galactosidase A (AGAL) activity. Our study demonstrates that repeated AGAL activity measurements in patients’ white blood cells at treatment-naïve baseline and during follow-up is mandatory to assess the in vivo amenability to migalastat. In addition, plasma lyso-globotriaosylceramide (lyso-Gb3) levels seem to be an appropriate tool to measure the biochemical response to migalastat. Patients with very low AGAL activities and increasing lyso-Gb3 levels despite in vitro amenability might not benefit sufficiently from chaperone treatment. (By Dr. rer. nat. Malte Lenders, )

(Visited 383 times, 1 visits today)